<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579381</url>
  </required_header>
  <id_info>
    <org_study_id>AHF 03</org_study_id>
    <nct_id>NCT03579381</nct_id>
  </id_info>
  <brief_title>Specimen Repository for HIV Immunopathogenesis</brief_title>
  <official_title>Specimen Repository for HIV Immunopathogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Healthcare Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specimen Repository for HIV Immunopathogenesis Studies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to build a large specimen repository for collaborating scientists to run studies&#xD;
      of immunity and HIV-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV progression from acute infection to viral suppression</measure>
    <time_frame>2 years</time_frame>
    <description>Outcomes will depend on scientists who use the samples for further study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV progression and control by elite and viremic suppressors</measure>
    <time_frame>2 years</time_frame>
    <description>Outcomes will depend on scientists who use the samples for study</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Acute HIV Infection</condition>
  <arm_group>
    <arm_group_label>Immune Controllers</arm_group_label>
    <description>Patients with very low or undetectable levels of viremia without treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Infection</arm_group_label>
    <description>Early infection, i.e. within 2 weeks of infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMCs and Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acutely HIV infected individuals HIV infected individuals who are not on anti-retrovirals&#xD;
        and have a viral load between 50 and 3,000 HIV infected individuals who are not on&#xD;
        anti-retrovirals and have a viral load less than 49&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV positive (acutely infected, viremic and elite controllers)&#xD;
&#xD;
          2. Signed Informed Consent Form&#xD;
&#xD;
          3. Age at least 18 years old&#xD;
&#xD;
          4. Immune controllers, two types: &quot;Elite suppressors&quot; (HIV-positive with any three&#xD;
             consecutive plasma HIV-1 RNA PCR undetectable while off treatment) or &quot;viremic&#xD;
             suppressors&quot; (HIV-positive with any three consecutive HIV-1 RNA PCR &lt;3000 while off&#xD;
             treatment).&#xD;
&#xD;
          5. Acutely infected subjects:&#xD;
&#xD;
        Persons identified to have a negative HIV antibody response (ELISA) but positive detection&#xD;
        of HIV-1 in the blood (RT-PCR) or individuals who have evidence of a recent (past 30 days)&#xD;
        HIV negative result along with a current HIV positive result.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled bleeding diathesis.&#xD;
&#xD;
          2. Pregnant.&#xD;
&#xD;
          3. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Otto O Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scientific Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation - Public Health Division</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

